Osivax is seeking to prevent influenza outbreaks by targeting a specific part of the virus
UNLOCK THIS INNOVATION AND MUCH MORE…
Become a member today and get early access to the ideas transforming our world from just £39 per month*
Exclusive member benefits:
- Access to over 13,000 innovations
- Monthly horizon scanning reports
- Exclusive feature articles
Already a member? Sign in here
Spotted: French-based Osivax is developing a universal flu vaccination designed to prevent various strains of the influenza virus for years. The vaccination will be more effective than current flu shots and will not need to be renewed annually.
“Currently available seasonal flu vaccines are limited in addressing all flu strains because they target highly variable regions of the virus,” said Alexandre Le Vert, CEO and co-founder of Osivax.
Osivax’s lead candidate version, OVX836, targets a particular part of the virus, the NucleoProtein. By targeting the NucleoProtein, it should stay effective even as the virus mutates. The formula has been successful in animal trials and is now being tested on humans.